Sartorius (SRT) Q3 2025 earnings summary

Executive summary

• Sales revenue grew 7.5% in constant currencies to €2,611 million for the first nine months, driven by strong recurring consumables demand across all regions, with Bioprocess Solutions leading growth and Lab Products & Services stabilizing.

• Underlying EBITDA margin expanded by 2 percentage points to 29.7%, reflecting operational leverage and efficiency gains despite FX headwinds and tariff impacts.

• Underlying net profit rose 17% to €244 million, and underlying EPS increased to €3.52 (ordinary).

• Leverage ratio reduced as planned, with commitment to investment-grade rating.

• Workforce expanded by 350 employees, mainly in production.

Financial highlights

• Sales revenue rose to €2,611 million (+7.5% cc) for 9M 2025; underlying EBITDA increased by 12.8% to €774 million, with margin up 2.0pp to 29.7%.

• Underlying EPS (ord.) grew 16.9% to €3.52; reported net profit up 66% to €125 million.

• Operating cash flow at €511 million, free cash flow at €200 million, both lower year-over-year due to higher working capital and capex.

• Capital expenditures totaled €305 million, 11.7% of sales revenue.

• Equity ratio improved to 39.7%; net debt/EBITDA reduced to 3.7x.

Outlook and guidance

• Full-year 2025 group sales growth expected at around 7% in constant currencies; Bioprocess Solutions at 9%, Lab Products & Services roughly flat.

• Underlying EBITDA margin forecast slightly above 29.5% for the group, above 31.5% for Bioprocess Solutions, and around 21.5% for Lab Products & Services.

• CapEx ratio guided at 12.5% of sales; net debt/EBITDA expected to decrease to approximately 3.5x by year-end.

• MATTEK acquisition to add about 1 percentage point to LPS sales growth; tariffs to contribute less than 1 percentage point to group sales but dilute EBITDA margin by ~30 basis points.